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ABSTRACT
Passage of hepatitis C virus (HCV) in human hepatoma cells resulted in populations that displayed partial resistance to alpha
interferon (IFN-), telaprevir, daclatasvir, cyclosporine, and ribavirin, despite no prior exposure to these drugs. Mutant spec-
trum analyses and kinetics of virus production in the absence and presence of drugs indicate that resistance is not due to the
presence of drug resistance mutations in the mutant spectrum of the initial or passaged populations but to increased replicative
fitness acquired during passage. Fitness increases did not alter host factors that lead to shutoff of general host cell protein syn-
thesis and preferential translation of HCV RNA. The results imply that viral replicative fitness is a mechanism of multidrug re-
sistance in HCV.
IMPORTANCE
Viral drug resistance is usually attributed to the presence of amino acid substitutions in the protein targeted by the drug. In the
present study with HCV, we show that high viral replicative fitness can confer a general drug resistance phenotype to the virus.
The results exclude the possibility that genomes with drug resistance mutations are responsible for the observed phenotype. The
fact that replicative fitness can be a determinant of multidrug resistance may explain why the virus is less sensitive to drug treat-
ments in prolonged chronic HCV infections that favor increases in replicative fitness.
Selection of viral mutants resistant to antiviral agents is a majorproblem for the successful treatment of viral diseases. In the
case of RNA viruses, high mutation rates during genome replica-
tion provide viral populations with an ample reservoir of pheno-
typic variants, including mutants that can escape selective con-
straints. Resistance to a single drug that targets a viral protein
develops at a rate that depends on the genetic barrier (number and
types of mutations needed to acquire resistance) and the pheno-
typic barrier (fitness cost) imposed by the resistance mutations
(1–16).When drug resistancemutations do not entail a significant
fitness cost—either because the mutations per se do not critically
affect viral functions or because compensatory mutations are ac-
quired—they may reach detectable levels despite no prior expo-
sure of the viral population to the drug (1, 16–27).
Control of hepatitis C virus (HCV) infections is hampered by
the complexity ofHCVquasispecies replicating in the liver (16, 28,
29). Directly acting antiviral agents (DAAs)—some currently in
use and others under development—offer great promise for con-
trol of HCV either as a substitute for or complement of the stan-
dard-of-care (SOC) therapy based on treatment using a combina-
tion of pegylated alpha interferon (IFN-) and ribavirin (30–36).
Combinations that include the polymerase inhibitor sofosbuvir
have produced sustained viral responses that in some cases have
been higher than 90% in clinical trials (37–40), but the possible
impact of resistancemutations is not known; sofosbuvir resistance
substitution S282T in NS5B is present in the sequence of HCV
reference isolate ED43 of genotype 4a and L159F is present in the
mutant spectrum of HCV quasispecies following treatment of
HCV p100 with ribavirin (I. Gallego, E. Domingo, and C. Perales,
unpublished results).
The advent of cell culture systems designed to achieve replica-
tion of full-length, infectious HCV (41–43) has opened the way to
studies on antiviral agents for HCV in cell culture. Using this
system (44), we performed up to 100 serial passages in the human
hepatoma Huh-7.5 cell line, either in the absence or the presence
of different concentrations of IFN- (45). In the course of these
studies, wemade the unexpected observations that populations of
HCV passaged in the absence of IFN- acquired partial resistance
to IFN- and that their capacity to shut off host cell protein syn-
thesis was increased relative to that of the parental virus HCV p0
(where “HCV p0” represents the HCV population before the first
passage in Huh-7.5 cells) (45). It was unlikely that selection for
partial IFN- resistance was due to endogenous IFN produced by
the host cell since the Huh-7.5 cells used for the infections are
defective in IFNproduction (46, 47). This observation raised three
issues: (i) what the difference is in replicative parameters between
HCV p0 and the passaged populations, (ii) whether the partial
Received 26 June 2014 Accepted 31 July 2014
Published ahead of print 13 August 2014
Editor: M. S. Diamond
Address correspondence to Esteban Domingo, edomingo@cbm.uam.es, or Celia
Perales, cperales@cbm.uam.es.
* Present address: Julie Sheldon, Institute of Experimental Virology, Twincore
Centre for Experimental and Clinical Infection Research, Hannover, Germany.
Dedicated to John J. Holland (1929-2013).
Copyright © 2014, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JVI.01860-14
12098 jvi.asm.org Journal of Virology p. 12098–12111 October 2014 Volume 88 Number 20
resistance is unique to IFN- or whether it extends to other anti-
HCVdrugs, and (iii) what themolecular basis is of either a specific
or general partial resistance to drugs.We addressed these issues in
the present study and show that passaged HCV displays increased
replicative capacity and diminished sensitivity not only to IFN-
but also to several other anti-HCV drugs. Furthermore, indepen-
dent HCV evolutionary lineages and biological clones display the
same behavior. Mutant spectrum analysis and viral replication in
the absence and presence of drugs render unlikely the possibility
that the presence of drug resistance mutations in the passaged
populations is responsible for the expanded drug resistance. The
results provide evidence that increased replicative HCV fitness
results in a multidrug resistance phenotype. Implications for
treatment of acute versus chronic HCV infections are discussed.
MATERIALS AND METHODS
Cells, viruses, and drugs.The origin ofHuh-7.5, Huh-7 Lunet, andHuh-
7.5 reporter cell lines and procedures for cell growth in Dulbecco’s mod-
ification of Eagle’s medium (DMEM) have been previously described (45,
48, 49); cells were cultured at 37°C and 5% CO2. Huh-7.5 cells were used
for titration of virus infectivity, and Huh-7.5 reporter cells were used for
standard infections and serial passages of HCV.
The viruses used in the experiments are those rescued from plasmids
Jc1FLAG2(p7-nsGluc2A) (a chimera of J6 and JFH-1 from genotype 2a),
termed HCV p0, and from plasmid GNNFLAG2(p7-nsGluc2A), termed
GNN (which carries amutation inNS5B that renders the virus replication
defective); GNN has been used as negative infection control, and both
viruses have been previously described (44). Preparation of the initial
HCV p0 population from the progeny of the initial electroporation with
the RNA transcripts and passage conditions in Huh-7.5 cells were previ-
ously described (45). Each virus passage involved infection of amonolayer
of 4  105 Huh-7.5 reporter cells with the number of infectious units
(measured as a 50% tissue culture infective dose [TCID50] value) indi-
cated in each experiment. To control for the absence of contamination,
the supernatants of mock-infected cells maintained in parallel with the
infected cultures were titrated; no infectivity in the mock-infected cul-
tures was detected in any of the experiments.
Biological clones were isolated from HCV populations by limiting
dilution followed by growth in Huh 7.5 cells. Briefly, HCV p0 and HCV
p100 populations were treated with sodium deoxycholate (0.01%) for 10
min at room temperature. Dilutions (103 to 107) were used to infect
Huh-7.5 cells in 96-well plates, and at 72 h postinfection (hpi), superna-
tants were collected and infected cells visualized by immunostaining with
anti-NS5A antibody (9E10). Viruses collected from wells containing a
single infected-cell focus were passaged twice on fresh Huh-7.5 cells,
yielding clonal populations with infectious titers of 104 to 105 TCID50/ml.
Each virus was then subjected to another round of limiting dilution as
described above, yielding final infectious virus stocks with titers of 105 to
106 TCID50/ml.
Stock solutions of 0.1 M ribavirin (Sigma), 10 mM telaprevir (Selleck
Chemicals), 10mMcyclosporine (Sigma), and 10mMdaclatasvir (Selleck
Chemicals) were prepared in phosphate-buffered saline (PBS) or H2O
and stored at70°C. Prior to use, the solutions were diluted in DMEM to
reach the desired concentration.
Virus titration. For titration of infectious HCV, samples were serially
diluted and applied to Huh-7.5 cells in 96-well plates (6,400 cells/well
seeded 16 h earlier). Three days later, cells were washed with PBS, fixed
with ice-cold methanol, and stained for the presence of NS5A using anti-
NS5A monoclonal antibody 9E10, as described previously (41, 45). The
virus titer was expressed as TCID50/ml (50).
Drug toxicity and inhibitory activity.Drug toxicity was measured in
Huh-7.5 reporter cells by seeding 96-well plates at 70% confluence and
exposing the cells to different drug concentrations for 72 h. Then,
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
was added to each well at a final concentration of 500 g/ml; following 4
h of incubation, 100l of dimethyl sulfoxide (DMSO)was added, and the
optical density at 550 nmwasmeasured. The drug concentration required
for 50% cell killing (CC50) was calculated as described previously (51).
The drug concentration required for 50% inhibition of infectious HCV
yield (IC50) was determined by seeding Huh-7.5 reporter cells in 96-well
plates to 70% confluence and infecting with HCV at a multiplicity of
infection (MOI) of 0.03 TCID50/cell. After incubation at 37°C for 5 h, the
inoculumwas removed andmediumwith orwithout dilutions of antiviral
drugs was added to eachwell. Infected cells were immunostained at 48 hpi
using anti-NS5A antibody (9E10), and the number of infected foci present
in each well was counted. IC50s were calculated by comparison of the
number of infected foci in each dilution of antiviral drug with the number
in the drug-untreated controls, using the program Sigma Plot. CC50 and
IC50 values were calculated as the averages of the results of at least three
determinations. The therapeutic index (TI  CC50/IC50) was calculated
for each drug.
Cell culture system for long-term serial passage of HCV. To initiate
serial passages of HCV, 4 105 Huh-7.5 reporter cells were infected with
HCV p0 at an MOI of 0.5 TCID50/cell, and virus adsorption was allowed
to proceed for 5 h at 37°C. Then, the inoculum was removed and 2 ml of
medium added to the cell monolayer. The infected cells were further in-
cubated at 37°C for 72 to 96 h. For each subsequent passage, 4  105
Huh-7.5 reporter cells were infected as described above using 0.5ml of cell
culture supernatant from the previous passage. The MOI for each infec-
tion was calculated from the infectivity values given for each experiment,
and it ranged between 0.1 and 0.5 TCID50/cell. Viral populations are iden-
tified with a “p” followed by the passage number (e.g., HCV p10 is HCV
p0 passaged 10 times in Huh-7.5 cells). Mock-infected cells and cells in-
fected with HCV p0 were maintained for 100 passages in parallel to con-
trol for the absence of contamination of cells with virus.
Infection in the presence of antiviral compounds.A fixed TCID50 of
12,800was used to infect 4 105Huh-7.5 cells (MOI 0.03TCID50/cell).
After 5 h of virus adsorption, supernatants were replacedwith freshmedia
with or without the antiviral compound. For subsequent passages, 0.5 ml
of the previously infected cell culture supernatant was used to infect 4
105Huh-7.5 reporter cells; infections were allowed to proceed for 72 to 96
h. For infections in the presence of ribavirin, cells were pretreated with
ribavirin for 16 h prior to infection.
RNA extraction, cDNA synthesis, PCR amplification, and nucleo-
tide sequencing. Intracellular viral RNAwas extracted from infected cells
after each passage using a Qiagen RNeasy kit (Qiagen, Valencia, CA),
according to the manufacturer’s instructions. Reverse transcription (RT)
was performed using avianmyeloblastosis virus (AMV) reverse transcrip-
tase (Promega), and PCR amplification of specific HCV genomic regions
was carried out using AccuScript (Agilent Technologies), with specific
oligonucleotide primers (45) (see Table S1 [http://www2.cbm.uam.es:80
80/cv-303/SupplMatSheldon.pdf]). Amplification products were ana-
lyzed by agarose gel electrophoresis, with theDNAsproduced by digestion
of-29 DNA with HindIII employed as molecular mass standards. Neg-
ative controls without template RNAwere included in parallel to ascertain
the absence of cross-contamination by template nucleic acids. Nucleotide
sequences of genomic HCV RNA were determined on the two strands of
an amplified cDNA copy (45, 52). To evaluate the complexity of mutant
spectra, HCV RNA was extracted as described above and subjected to
RT-PCR to amplify the NS5A-coding regions as previously described
(53). To ensure an excess of template in the RT-PCR amplifications for
quasispecies analysis, and to avoid complexity biases due to redundant
amplifications of the same initial RNA templates, amplifications were
carried out with template preparations diluted 1:10, 1:100, and 1:1,000;
only when the template diluted 1:100 produced a visible DNA band was
molecular cloning pursued using the DNA amplified from the undiluted
template. Controls to ascertain that the mutation frequencies were not
affected by the basal error rate during amplification have been previously
described (54).
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For the ultradeep pyrosequencing (UDPS) analysis (GS-FLX plat-
form; 454 Life Sciences-Roche), RT-PCRwas performed using Accuscript
(Agilent). To cover the complete NS5A region, and considering that the
GS-FLX Titanium chemistry allows sequencing fragments of 400 to 500
nucleotides, this genomic region was divided into six overlapping ampli-
cons, and amplification products were obtained using specific primers
(see Table S1 [http://www2.cbm.uam.es:8080/cv-303/SupplMatSheldon
.pdf]). To minimize the errors due to PCRs, RT-PCR amplifications were
performed in triplicate, and the amplification products weremixed equimo-
larlyprior to theanalysis.Then,PCRproductswerepurified(Ampurebeads),
quantified (Pico green assay), and analyzed for quality (Bioanalyzer) prior to
theUDPSprocedure.Negative controls (without template RNA)were run in
parallel to ascertain the absence of contamination with undesired templates.
Procedures for the data analysis have been previously described (53). The
genomic nucleotide sequences of the HCV described in the present study
have been deposited in GenBank (see below).
Quantification of HCV RNA using real-time RT-PCR. Real-time
quantitativeRT-PCR(qRT-PCR)ofHCVRNAwascarriedoutusingaLight-
Cycler RNAMaster SYBR green I kit (Roche) (41, 45). The 5= untranscribed
region (5=-UTR) of the HCV genome was amplified using as primers oligo-
nucleotides HCV-5UTR-F2 and HCV-5UTR-R2 (see Table S1 [http://www
2.cbm.uam.es:8080/cv-303/SupplMatSheldon.pdf]). Quantification was per-
formed relative to a standard curve obtained with known amounts of HCV
RNA, synthesized by in vitro transcription of plasmid GNNFLAG2(p7-
nsGluc2A).The specificity of the reactionwasmonitoredby thedenaturation
curve of the amplified DNAs. Negative controls (without template RNA and
RNA frommock-infected cells) were run in parallel with each amplification
reaction to ascertain the absence of contaminationwith undesired templates.
Quantifications were carried out in triplicate.
Relative-fitness assays. Relative fitness was measured by growth-
competition experiments between two viruses in Huh-7.5 cells. Compe-
titions were established between HCV p0 and either HCV p45 or HCV
p100 and also between HCV p45 and HCV p100. To this end, 4  105
Huh-7.5 cells were infected with a 1:1 mixture of the two competing
viruses based on infectivity values (total, 1.2 104 TCID50; MOI of 0.03
TCID50/cell). RNA extracted from the initial mixtures and from infected
cells at 24, 48, and 72 h postinfection was sequenced in regions that con-
tained mutations diagnostic of each population (45). The ratio of the two
competing viruses at each time point was estimated by measuring the
areas of the relevant chromatogram peaks, as described previously (45,
52). The logarithm of this ratio was plotted against the time postinfection,
and the fitness vector was adjusted to the following exponential equation:
y a ebx. The antilogarithm of the vector slope gives the relative rep-
licative fitness of the competing viruses.
Pulse-labeling of infected cells andWesternblot assays.Protein syn-
thesis was analyzed by metabolic labeling of uninfected or infected cells
with [35S]methionine (Met)-cysteine (Cys), followed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of protein ex-
tracts and fluorography, using previously described procedures (45). Pro-
teins were labeled by the addition of 60Ci of [35S]Met-Cys (Amersham)
perml contained inmethionine-free DMEMat 72 h postinfection. After 1
h of incubation of the cell monolayers with the radioactive medium, the
latter was removed and the cells were harvested in 0.2 ml of sample buffer
(160 mM Tris-HCl [pH 6.8], 2% SDS, 11% glycerol, 0.1 M dithiothreitol
[DTT], 0.033% bromophenol blue). The samples were boiled for 5 min,
and aliquots were analyzed by SDS-PAGE at 200 V. Fluorography and
autoradiography of the gels were done as previously described (55). The
amount of cell extract used for electrophoretic analysis was normalized to
the amount of cellular actin, measured by reactivity with a specificmono-
clonal antibody (anti--actin clone AC-15; Sigma).
ForWestern blot assays, proteins were transferred to a 0.45-m-pore-
size nitrocellulose membrane (Bio-Rad); blots were developed with the
following antibodies: mouse monoclonal anti-NS5A (9E10) at a dilution
of 1:1,000; mouse monoclonal anti-core (Santa Cruz Biotechnology) at a
dilution of 1:200; mouse monoclonal anti--actin (clone AC-15; Sigma)
at a 1:1,000 dilution; rabbit polyclonal anti-eukaryotic initiation factor 3
subunit a (anti-eIF3a), anti-eIF3b, and anti-eIF4B antibodies (Novus) at a
1:2,000 dilution; rabbit polyclonal anti-eIF4G and anti-poly(A)-binding
protein (anti-PABP) antibodies at a 1:2,000 dilution; anti-polypyrimidine
FIG 1 Evolution of HCV infectivity and RNA during 100 passages in cell
culture. (Top gray panel) Scheme of the origin ofHCVpopulations. The initial
clonal population (HCVcc) obtained by electroporation of Lunet cells by an
HCV transcript is depicted as a filled square, and subsequent population pas-
sages are represented by empty circles; GNN is a replication defective mutant
of HCVcc used as negative control. (White panels) Infectious viral titers of the
supernatants, extracellular and intracellular viral RNA levels (quantified by
real-time RT-PCR), and multiplicity of infection (M.O.I.) as a function of
passage number. The crosses in the abscissae of the first panel indicate mea-
surements upon serial infection with mutant GNN. Arrows indicate the pas-
sage number (passage 60) after which the MOI was decreased to prevent cell
lysis. The origin of HCV, conditions for infections, determination of HCV
infectivity, and quantification of HCV RNA, as well as positive and negative
controls included in the assays, are described in Materials and Methods.
Sheldon et al.
12100 jvi.asm.org Journal of Virology
FIG 2 Comparison of phenotypic traits of HCV p0, HCV p45, and HCV p100 (symbols in upper left box). (A and B) The effect of adsorption time on the yield
of infectious progeny.Huh-7.5 cells were eithermock infected or infectedwithHCVp0,HCVp45, orHCVp100 at anMOI of 0.03 TCID50/cell (4 10
5Huh-7.5
cells infected with 1.2 104 TCID50). The virus was adsorbed to cells for the indicated times, the cells were washed twice with PBS, and DMEMwas added to the
monolayers. Infectivity levels in the cell culture supernatant were determined at 72 h postinfection. (C and D) HCV p0, HCV p45, and HCV p100 progeny
production in Huh-7.5 cells. Infections were performed as described for panels A and B, using a 5-h adsorption period. Infectivity levels in the cell culture
supernatant and intracellular viral RNA levels were determined at 72 h postinfection. (E) Relative fitness of HCV p0, HCV p45, and HCV p100. A single
growth-competition experiment was performed by infecting Huh-7.5 cells with the viral mixtures indicated in the abscissa (MOI  0.03 TCID50/cell). The
relative amounts of the competing viruses were determined at 24, 48, and 72 h postinfection. Viral RNA present in the initial mixtures and at each passage was
sequenced, and the proportions of the two competing populations were estimated and fitness data were calculated as detailed in Materials and Methods.
Numerical values are given inTable S2 (http://www2.cbm.uam.es:8080/cv-303/SupplMatSheldon.pdf). (F) Infection of Lunet,Huh-7, andHuh-7.5 cells byHCV
p0 and p100. Infections were performed as described for panels A and B, with a 5-h adsorption period. Infectivity levels in the cell culture supernatant were
determined at 72 h postinfection. (G) Thermal stability of HCV p0, HCV p45, andHCV p100. Virus samples in DMEMwere incubated at 45°C for the indicated
amounts of time and titrated. Values are averages of the results of triplicate determinations. Procedures are further detailed in Materials and Methods.
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tract-binding protein (anti-PTB) at a 1:3,000 dilution (56); mousemono-
clonal anti-tubulin (Sigma) at a 1:5,000 dilution; rabbit polyclonal anti-
eIF2 phosphospecific antibody (Invitrogen) at a dilution of 1:300; and
rabbit polyclonal anti-eIF2 (Santa Cruz Biotechnology) at a dilution of
1:200. Goat anti-mouse IgG (Pierce) and donkey anti-rabbit IgG (Amer-
sham) coupled to peroxidase were used at a 1:10,000 dilution. The
amount of protein extract used to determine the relative intensities of viral
and cellular proteins corresponded to the linear region in the relationship
between concentrations of protein extract and band intensity determined
by Western blot analysis.
Measurements of infectivity decay. Equal TCID50s of viral samples of
HCVp0,HCVp45, andHCVp100were incubatedat 45°C, andaliquotswere
collectedatdifferent timepoints and titrated.Thevalues corresponding to the
decay of virus titer over time were fitted to an exponential curve, and the
inactivation rate constant was calculated as previously described (57).
Statistical analyses. The statistical significance of differences between
mutation frequencies was evaluated by the chi-square test (	2 test). To
determine the statistical significance of differences in infectivity decay and
IC50 values, one-way analysis of variance (ANOVA) was performed with
the SPSS 13.0 statistical package (SPSS, Inc.). For the differences deter-
mined in serial-passage experiments, two-way ANOVA was used. For
multiple comparisons, Bonferroni’s correction was applied.
Nucleotide sequence accession numbers. The genomic nucleotide
sequences of the HCV described in the present study have been deposited
in GenBank with accession numbers KC595606 to KC595624.
RESULTS
Intracellular replication and particle stability of HCV p0 and
HCV p100.HCV p0 was subjected to 100 serial passages in Huh-
7.5 cells, and infectivity in the cell culture supernatant, as well as
intracellular and extracellular viral RNA levels, was measured at
each passage (Fig. 1). By passage 60, the viral population displayed
increased cytopathology that could alter the intracellular-to-ex-
tracellular-RNA ratios and diminish the number of cells and du-
ration of replication cycles. To avoid confounding effects derived
from cell killing, beginning at passage 60, the MOI was reduced
about 10-fold (Fig. 1). HCV passaged in Huh-7.5 cells in the ab-
sence of IFN- acquired partial resistance to IFN- (45). To ex-
plore the basis of such resistance, the replication dynamics, fitness,
and thermal stability characteristics of HCV p0, HCV p45, and
HCV p100 were compared (Fig. 2). Viral progeny production in-
creased with passage number (HCV p100
HCV p45
HCV p0)
independently of the time allowed for virus adsorption to cells (Fig.
2A and B). The selective advantage of passaged HCV was associated
with increased infectious particle production (P  0.03 in all com-
parisons; ANOVA test) and intracellular replication (Fig. 2C andD),
an advantage further confirmed by a relative HCV p100/HCV p0
replicative-fitness ratio of 2.2 0.4 (Fig. 2E; see also Table S2 [http:
//www2.cbm.uam.es:8080/cv-303/SupplMatSheldon.pdf]). Since Lu-
net, Huh-7, and Huh-7.5 cells may allow viral multiplication at
different rates (58), we examined whether extensive passage of
HCV resulted in a differences in the capacity to infect the three cell
lines. The ratios of the yield of HCV p100 to that of HCV p0 were
very similar in all cell lines, as evaluated in a single infectious cycle
(Fig. 2F). The three HCV populations displayed indistinguishable
thermal-stability results, with inactivation rate constants at 45°C
of k 0.00756 0.00658 (corresponding to a half-life of 91 min)
for HCV p0, k 0.00813 0.00691 for HCV p45 (corresponding
to a half-life of 85min), and k 0.00733 0.00631 forHCVp100
(corresponding to a half-life of 94 min); the differences were not
statistically significant (P 0.13 to 1; ANOVA test) (Fig. 2G). This
result excluded the possibility that an increase in thermal stability
(selected during passaging) influenced the replicative-fitness val-
ues. Thus, the parameter associatedwith partial resistance ofHCV
p100 to IFN- was a more efficient intracellular replication pro-
cess that resulted in increased progeny production.
Response of passaged HCV to antiviral inhibitors. To test
whether the partial resistance of HCV p45 and p100 to IFN- (45)
was a consequence of specific features of the antiviral activity evoked
by IFN- (59), resistance to ribavirin, telaprevir, daclatasvir, and cy-
closporine, drugs that display unrelated mechanisms of activity, was
investigated. The drug concentrations required to achieve a 50% in-
hibition of infectious HCV progeny production (IC50) were higher
for the passaged HCV populations than for the parental HCV p0
populations (Table1).Thedifferencesbetween theHCVp45orHCV
p100 values and the HCV p0 IC50 values were statistically significant
(P  0.01; ANOVA test), but the difference between the HCV p45
and HCV p100 values was not (P
 0.05; ANOVA test). The thera-
peutic index(TI) for eachdrugandeachviruswascalculated fromthe
CC50 and IC50 values (see Table S3 [http://www2.cbm.uam.es:8080
/cv-303/SupplMatSheldon.pdf]). As expected, passaged HCV dis-
played lower TI values than the parental HCV p0.
The increased resistance of HCV p45 and HCV p100 to the
drugs relative to that of HCV p0 was also evident upon serial viral
passages (Fig. 3), with loss of detectable infectivity of HCV p0 by
passage 5 in the presence of ribavirin, telaprevir, or cyclosporine
and yields of HCV p100 above 105 TCID50/ml; differences among
the three viruses were statistically significant in the absence of
drug and in the presence of IFN- or ribavirin (P 0.01; ANOVA
test). In the presence of telaprevir, daclatasvir, and cyclosporine,
the differences seen with comparisons of HCV p45 or HCV p100
to HCV p0 were statistically significant (P 0.001; ANOVA test),
but the differences seen with comparisons of HCV p45 to HCV
p100 were not statistically significant (P 
 0.05; ANOVA test).
The sensitivity of HCV p0 to daclatasvir decreased with passage
number (Fig. 3). HCVp100 displayed resistance to higher telapre-
vir and ribavirin concentrations also (see Fig. S1).
Sequence analysis of the consensus sequence of the NS5A-cod-
ing region at passage 10 revealed the presence of substitution
F28C, a position involved in daclatasvir resistance. To determine
whether resistancemutationswere selected uponpassages ofHCV
p45 and HCV p100 in the presence of the drugs, the consensus
sequences corresponding to NS3-coding regions (for telaprevir),
NS5A-coding regions (for daclatasvir and cyclosporine), and
NS5B-coding regions (for ribavirin) at passage 10 were analyzed.
Mutations conferring resistance to telaprevir and daclatasvir were
frequently selected (see Tables S3 to S6 [http://www2.cbm.uam
.es:8080/cv-303/SupplMatSheldon.pdf]), as expected from the
TABLE 1 Quantification of inhibition of HCV p0, HCV p45, and HCV
p100 infectious progeny production by antiviral agentsa
Antiviral
agent CC50 SD
IC50 SD
HCV p0 HCV p45 HCV p100
Ribavirin 108 4.2 M 6.9 0.9 M 23 2 M 20 4 M
Telaprevir 22,000 3,200 nM 87 18 nM 273 67 nM 302 75 nM
Daclatasvir 14,900 600 nM 10 0.3 pM 63 3 pM 78 18 pM
Cyclosporine 
50,000 nM 83 22 nM 343 130 nM 358 95 nM
a Determinations of 50% cytotoxic concentrations (CC50) and 50% inhibitory
concentrations (IC50) were carried out in triplicate. Average values and standard
deviations were calculated using the program Sigma Plot. Experimental conditions for
cell growth, HCV infection, and determinations of cell viability and HCV infectivity are
described in Materials and Methods.
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low barrier to resistance of these drugs (60, 61). HCV lineages,
other than the ones depicted in Fig. 1, that were described in our
previous study (45) also displayed increased resistance to the
drugs relative to HCV p0 (see Fig. S2 at the URL mentioned
above). Thus, serial passage of HCV p0 in Huh-7.5 cells led to
populations that displayed resistance to several anti-HCV agents
that target different viral or cellular factors, despite no prior expo-
sure of the viral populations to the corresponding drugs.
Molecular basis of expanded HCV drug resistance. Replica-
tion rate, population complexity, and replicative fitness are inter-
connected parameters that have been linked to the adaptability
and pathogenic potential of viral populations (16, 62–66). To de-
termine whether extensive passage of HCV in Huh-7.5 cells re-
sulted in an expanded mutant spectrum, mutation frequency,
Shannon entropy, mutation types, and numbers of polymorphic
sites and haplotypes at the NS5A-coding region were determined
for populations of HCV p0, HCV p45, and HCV p100, using mo-
lecular cloning and Sanger sequencing and ultradeep pyrose-
quencing (UDPS). The mutation frequency among components
of the mutant spectrum increased 2.6-fold from HCV p0 to HCV
p100 (P  0.0001; 	2 test), and the Shannon entropy reached its
maximumpossible value (Table 2). UDPS indicated an increase of
the numbers of different mutations, polymorphic sites, and hap-
lotypes in HCV p45 and HCV p100 relative to HCV p0 (Table 3).
Transitions amounted to 75% to 77% of the total number of mu-
tations, and the ratio [(G¡A)(C¡U)]/[(A¡G)(U¡C)] was
maintained in the range of 0.21 to 0.69 (see Fig. S3), as expected
for HCV not subjected to a mutagenic agent (53). The amino acid
substitutions deduced from theNS5Amutant spectra ofHCVp45
and HCV p100 did not reveal any substitutions (F28S, L31M,
C92R, and Y93H) currently catalogued as conferring resistance to
daclatasvir (67–73) (see Tables S7 and S8). However, substitution
F28I was present at a 0.75% level in the mutant spectrum of HCV
p100 (see Table S9 [http://www2.cbm.uam.es:8080/cv-303/Suppl
MatSheldon.pdf]) but did not become dominant upon passage of
HCV p100 in the presence of daclatasvir (see Table S6 at the URL
mentioned above). In the case of cyclosporine, the mutations that
lead to resistance substitution V464L were present in the quasi-
species of HCV p0 and HCV p45 but not in HCV p100 (see Table
S9 at the URL mentioned above). Furthermore, this substitution
did not become dominant upon passage in the presence of cyclo-
sporine (see Table S7 at the URLmentioned above). Therefore, an
FIG 3 Response of HCV p0, HCV p45, and HCV p100 to several antiviral
agents. Huh-7.5 cells were eithermock infected or infectedwithHCVp0,HCV
p45, or HCV p100 at an MOI of 0.03 TCID50/cell (4  10
5 Huh-7.5 cells
infected with 1.2 104 TCID50); the virus was adsorbed to cells for 5 h and the
infection allowed to proceed for 72 h. Each of the populations was subjected to
10 passages in the absence or presence of IFN- (HCV p45 passaged in the
presence of 2 IU/ml and HCV p100 with 12 IU/ml, as previously described
[45]), ribavirin (Rib) (50 M), telaprevir (TPV) (600 nM), daclatasvir (DCV)
(500 pM), or cyclosporine (CsA) (800 nM). The passages in the presence of
IFN- that had been previously described are included here for comparison.
For the successive passages, the same numbers of cells were infected with the
virus contained in 0.5ml of the supernatant from the previous infection,main-
taining the same drug concentration, and viral titers in the cell culture super-
natants were determined. Parallel infections were carried out with HCV GNN
as a negative control. Procedures are described in Materials and Methods.
TABLE 2 Quasispecies analysis of HCV p0, HCV p45, and HCV p100 populationsa
Virus
No. of nucleotides analyzed
(no. of clones/no. of haplotypes)b
Total no. of
mutationsc
No. of different
mutationsd
Mutation frequency
Shannon
entropygMaximume Minimumf
HCV p0 37,746 (27/19) 32 30 8.5 104 7.9 104 0.78
HCV p45 41,940 (30/30) 133 57 3.2 103 1.4 103 1
HCV p100 40,542 (29/29) 298 83 7.4 103 2.1 103 1
a The populations analyzed correspond to passages 0, 45, and 100 of the infections described in the Fig. 1 legend. The genomic region analyzed was that of NS5A (nt 6269 to 7666).
The HCV genome residue numbering corresponds to the JFH-1 genome (GenBank accession number AB047639).
b The values in parentheses indicate the number of clones analyzed, followed by the number of haplotypes (numbers of different RNA sequences).
c Data represent the total number of mutations found by comparing the sequence of each individual clone with the reference (parental) sequence.
d Data represent the number of different mutations found by comparing the sequence of each individual clone with the reference (parental) sequence.
e Data represent the average number of total mutations per nucleotide relative to the reference (parental) sequence.
f Data represent the average number of different mutations per nucleotide relative to the reference (parental) sequence.
g Shannon entropy (S) is a measure of the number of different molecules in the mutant spectrum of the quasispecies. It is calculated by the formula S[i (pi ln pi)]/ln N, in
which pi is the frequency of each sequence in the quasispecies and N is the total number of sequences compared.
Fitness and Drug Sensitivity
October 2014 Volume 88 Number 20 jvi.asm.org 12103
F28I substitution or a V464L substitution cannot explain the re-
sistance of HCV p45 and HCV p100 to these drugs.
It is probable that not all drug resistance mutations in HCV
have been identified. To further exclude the possibility that the
presence of inhibitor resistance mutations may underlie the
observed decrease of viral sensitivity to inhibitors, the MOI in
the serial infections was decreased up to 1,000-fold. The kinet-
ics of HCV progeny production followed anMOI-independent
pattern (Fig. 4). The differences between the increases in viral
titers in the passages in the absence of drug and either telaprevir
or cyclosporine were not significant at any MOI tested (P 
0.724 to 1 and P  0.187 to 1, respectively; ANOVA). The
difference in the case of ribavirin reached significance at all
MOI (P 0.01 to 0.032) except at an MOI of 0.03 TCID50/cell
(P  0.065; ANOVA). This result is not compatible with an
increase of the frequency of mutations conferring resistance to
TABLE 3 Ultradeep pyrosequencing analysis of hepatitis C virus populations HCV p0, HCV p45, and HCV p100a
Parameter Virus
Value(s) for indicated NS5A amplicon (no. of haplotypes with 1, 2, 3, 4, 5, and 6 mutations)b
A1 (residues
6152–6454)
A2 (residues
6446–6767)
A3 (residues
6737–6954)
A4 (residues
6910–7252)
A5 (residues
7224–7550)
A6 (residues
7432–7725)
No. of different
mutations
HCV p0 1 6 4 9 6 9
HCV p45 6 12 10 14 13 19
HCV p100 21 14 16 29 21 17
No. of polymorphic
sites
HCV p0 1 6 4 9 6 7
HCV p45 6 11 10 13 13 18
HCV p100 20 14 15 29 20 16
No. of haplotypesc HCV p0 2 (1/0/0/0/0/0) 7 (6/0/0/0/0/0) 5 (4/0/0/0/0/0) 9 (7/1/0/0/0/0) 6 (4/1/0/0/0/0) 10 (9/0/0/0/0/0)
HCV p45 7 (6/0/0/0/0/0) 13 (11/1/0/0/0/0) 11 (10/0/0/0/0/0) 14 (10/3/0/0/0/0) 14 (7/2/3/1/0/0) 26 (9/6/4/6/0/0)
HCV p100 29 (9/6/9/3/1/0) 18 (7/6/3/0/1/0) 17 (15/1/0/0/0/0) 29 (8/13/5/2/0/0) 19 (10/3/5/0/0/0) 26 (6/6/5/5/2/1)
a The populations analyzed correspond to passages 0, 45, and 100 of the infections described in the Fig. 1 legend.
b The HCV genome residue numbering corresponds to the JFH-1 genome (GenBank accession number AB047639). Amplicon (A) length ranged between 216 and 339 nucleotides.
The number of nucleotides sequenced was 2.1 106 to 3.3 106, and the number of reads on which the parameters were calculated was 10,000 for each amplicon. Procedures are
described in Materials and Methods.
c The numbers of haplotypes with one, two, three, four, five, and six mutations are given in parentheses; no haplotypes with a higher number of mutations were found. Mutation
types are summarized elsewhere (see Fig. S3), and their positions in the HCV genome and deduced amino acid substitutions are given in Table S9 (the relevant tables can be found
at http://www2.cbm.uam.es:8080/cv-303/SupplMatSheldon.pdf).
FIG 4 Effect ofMOI on the response ofHCVp0 andHCVp100 to several antiviral agents in cell culture. Huh-7.5 cells were eithermock infected or infected with
HCV p0 orHCV p100 at anMOI of 0.03, 0.003, 0.0003, and 0.00003 TCID50/cell (top boxes) (4 10
5Huh-7.5 cells infected with 1.2 104, 1.2 103, 1.2 102,
and 1.2 101 TCID50, respectively); the virus was adsorbed to cells for 5 h and the infection allowed to proceed for 72 h. Each of the populations was subjected
to 3 passages in the absence or presence of telaprevir (TPV) (600 nM), cyclosporine (CsA) (800 nM), or ribavirin (Rib) (50M). For the successive passages, the
same numbers of cells were infected with the virus contained in 0.5ml of the supernatant from the previous infection, maintaining the same drug concentration.
Viral titers in the cell culture supernatants were determined. Parallel infections were carried out with HCVGNN as a negative control. Procedures are described
in Materials and Methods.
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telaprevir and daclatasvir in HCV p100. The variation of sta-
tistical significance with MOI in the case of ribavirin is not easy
to interpret since under our infection conditions ribavirin acts
as both an inhibitor and a mutagen (53). Resistance to telapre-
vir was examined with more detail. Infectious progeny produc-
tion by individual biological clones derived from HCV p0 and
HCV p100 in the absence or presence of telaprevir was indis-
tinguishable from that seen with the corresponding parental
populations (P  0.24 to 1 for HCV p0 clones; P  1 for HCV
p100 clones, in the absence of telaprevir; P  1 for HCV p0
clones; P  0.14 to 1 for HCV p100 clones, in the presence of
telaprevir [ANOVA]); the difference between the uncloned
populations of HCV p0 and HCV p100 was significant (P 
0.045; ANOVA) (Fig. 5). Thus, the multidrug resistance phe-
notype of passaged HCV is associated with its replicative fitness
and is not due to the presence of inhibitor resistance muta-
tions.
Alterations of host cell protein synthesis upon HCV infec-
tion. The replicative capacity of a virus is often determined by the
presence of multiple viral expression products in interaction with
host factors. Virus infection, as well as apoptosis, may result in
cleavage of several translation initiation factors (eIFs) and thus in
a decrease of 5=-cap-dependent protein synthesis without affect-
ing ribosome entry site (IRES)-dependent viral protein synthesis,
as is the case with HCV and picornavirus RNA (74, 75). This is
partly mediated by disruption of critical components of the pro-
tein synthesis preinitiation complex consisting of eIF4G, eIF3, and
poly(A)-binding protein (PABP) (56, 76–82). Previous work in-
FIG 5 Replication of biological clones derived from HCV p0 and HCV p100 in the absence and presence of telaprevir. (A) Scheme of the procedure to obtain
clonal preparations from populations of HCV p0 and HCV p100. Mild-detergent-treated virus was diluted and applied to M96 wells with a Huh-7.5 cell
monolayer. Cell culture supernatant fromwells with a single cluster of infected cells was used to infect Huh-7.5 cells inM24 wells, and the supernatant was again
transferred to a M6 dish with Huh-7.5 cells. The final round of amplification consisted of infecting 5.2  105 Huh-7.5 cells in a p60 dish under the standard
conditions detailed in Materials and Methods. (B) Huh-7.5 cells were either mock infected or infected with uncloned populations HCV p0 and HCV p100, and
with three biological clones from each population, at anMOI of 0.03 TCID50/cell (4 10
5 Huh-7.5 cells infected with 1.2 104 TCID50); the virus was adsorbed
to cells for 5 h and the infection allowed to proceed for 72 h in the absence and presence of telaprevir (TPV; 600 nM). For the successive passages, the same
numbers of cells were infected with the virus contained in 0.5ml of the supernatant from the previous infection, maintaining the same drug concentration. Viral
titers in the cell culture supernatants were determined. Parallel infections were carried out with HCV GNN as a negative control. Procedures are described in
Materials and Methods.
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FIG 6 Effect of HCV p0, HCV p45, and HCV p100 infection on host cell protein synthesis and translation initiation factors. (A) Huh-7.5 cell were either mock
infected or infected with HCV p0, HCV p45, or HCV p100 at anMOI of 0.03 TCID50/cell (4 10
5 Huh-7.5 cells infected with 1.2 104 TCID50), and the virus
was allowed to adsorb to cells for 5 h. At 24, 48, and 72 h postinfection (h.p.i), cells were labeled with [35S]Met-Cys for 1 h, and cell extracts were subjected to
SDS-PAGE and visualized by autoradiography. The total amount of labeled protein was calculated by densitometry measurements of the corresponding
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dicated that HCV p100 produced a larger shutoff of host cell pro-
tein synthesis than the parental HCV p0, and the change was as-
sociated with increased phosphorylation of protein kinase R
(PKR) and eIF2 (45). To study whether cleavage of other host
factors required for translation control was involved in the repli-
cative advantage of passaged HCV, we compared results revealing
the shutoff of host cell protein synthesis and the integrity of initi-
ation factors eIF4G, eIF3a, eIF3b, eIF4B, PABP (80), and IRES-
transacting factor polypyrimidine tract-binding protein (PTB)
(83, 84) in Huh-7.5 cells, following infection with HCV p0, HCV
p45, orHCVp100. Enhanced shutoff of host cell protein synthesis
at late times postinfection by passaged HCV (Fig. 6A) was accom-
panied by increased virus-specific protein synthesis (Fig. 6B) and
production of infectious progeny (Fig. 6C). No cleavage of any of
the factors tested was observed (Fig. 6D). In the same infections,
phosphorylation of eIF2 and PKR was increased at 72 h postin-
fection (Fig. 6E), in agreement with previous results (45, 46, 85).
Thus, the enhanced replication of HCV and the diminished host
cell protein synthesis achieved upon extensive passage in Huh-7.5
hepatoma cells was associated with increased phosphorylation of
eIF2 and PKR and did not require cleavage of translation initia-
tion factors controlling 5=-cap-dependent translation initiation.
The enhanced phosphorylation of eIF2 and PKRwas established
independently of the degree of adaptation of HCV to the host cell
(45, 46, 85).
DISCUSSION
Serial passage of HCV in Huh-7.5 cells resulted in populations
that display increased replicative fitness and partial resistance to
inhibitors that target viral or cellular proteins. The partial resis-
tance extends also to ribavirin, which acts as an HCV mutagen in
our experimental system (53). Despite an expansion of themutant
spectrum complexity during HCV passage in Huh-7.5 cells (Ta-
bles 2 and 3), the drug resistance phenotype was not due to the
presence of any inhibitor resistance mutations that might have
accumulated in the expanded mutant spectrum of HCV. This
conclusion is supported by different observations. (i) Several well-
characterized inhibitor resistance mutations of HCVwere not de-
tected in the mutant spectra of HCV p45 and HCV p100 (see
Tables S8 and S9 [http://www2.cbm.uam.es:8080/cv-303/Suppl
MatSheldon.pdf]). Substitution F28I in NS5A affected the same
amino acid of the F28S daclatasvir resistance mutation (73).
UDPS identified F28I as present at a 0.75% frequency in the mu-
tant spectrum of HCV p100. Upon passage of HCV p100 in the
presence of daclatasvir, F28I did not become dominant, but F28S
did. It cannot be argued that F28I was an intermediate substitu-
tion required to reach F28S since substitution I28S requires two
mutations while F28S requires only one (see Tables S6 and S9 at
the URL mentioned above). Concerning cyclosporine, resistance
substitution V464L (86) in NS5A was present in the mutant spec-
trum of HCV p0 and HCV p45 but not in that of HCV p100 (see
Table S9 at the URL mentioned above). Furthermore, V464L did
not become dominant upon passage of HCV p45 and HCV p100
in the presence of cyclosporine (see Table S7 at the URL men-
tioned above). (ii) Reductions in the infecting MOI did not affect
the kinetics of viral production in the presence of inhibitors (Fig.
4). If progeny production were dependent on the presence of re-
sistance mutations, a 1,000-fold decrease in MOI should have de-
layed viral production in the presence of the inhibitors (5, 87–89).
(iii) Biological clones isolated from HCV p0 and HCV p100 pop-
ulations in the absence of inhibitors responded to telaprevir in a
manner similar to that seen with their parental, uncloned popu-
lations (Fig. 5). The biological clones were obtained by limiting
dilution and were grown to form a minimal working stock (see
Materials and Methods). The total number of virus production
rounds undergone by the biological clones was at least 3-fold
lower than the number of rounds involved in the preparation of
HCV p0, a population that did not display drug resistance. Thus,
the cloning procedure used should have excluded genomes with
drug resistance mutations.
The drug resistance phenotype was associated with increased
replicative fitness (Fig. 2). Fitness is expected to increase upon
virus replication in a constant environment (90–92). High foot-
and-mouth disease virus (FMDV) and human immunodeficiency
virus type 1 (HIV-1) fitness rendered the viruses partially resistant
to lethal mutagenesis (93–95), but a fitness effect in general drug
resistance has not been reported. Reduced replication fitness of
genotype 2a NS2-5B replicons increased sensitivity to cyclospo-
rine and some other inhibitors but not sensitivity to telaprevir
(96). High HCV replicative fitness increased the levels of eIF2
and PKR phosphorylation produced by the parental HCV but, in
contrast to other viruses using IRES-dependent translation initi-
ation of their genomic RNA (56, 79–82), did not induce cleavage
of factors needed for host cell protein synthesis (Fig. 6). Thus, at a
high level of replicative fitness, HCVmaintained the mechanisms
that result in shutoff of host cell protein synthesis and preferential
IRES-dependent translation of the RNAwhen eIF2 is phosphor-
ylated (46, 85, 97, 98). The increase in the intracellular replicative
load that enhances eIF2 and PKR phosphorylation may also un-
derlie the drug resistance phenotype. High levels of replicating
RNA and RNA expression products may confer a selective advan-
tage in competition with the number of inhibitor molecules that
reach the target viral or cellular proteins at the replication com-
plex.
The results of the present study suggest that cross-resistance
among antiviral inhibitorsmay come about not only through spe-
cific amino acid substitutions that confer resistance to more than
one drug but also through a general increase in viral fitness, with-
out involving specific drug resistance mutations. Studies are now
in progress to attempt to map those mutations that, among the
many accumulated in the consensus sequence of HCV p100 and
its mutant spectrum (see Tables S8 and S9 [http://www2.cbm
.uam.es:8080/cv-303/SupplMatSheldon.pdf]) (45), might be in-
autoradiograms and is expressed as a percentage of the amount of actin protein taken as 100%. (B) HCV protein expression at 24, 48, and 72 h postinfection. Infected
Huh-7.5proteinextractswere thoseof the experimentdescribed forpanelA.HCVNS5Aandcorewere stainedbyWesternblottingusingmonoclonal antibodies specific
for the proteins indicated on the right side of the panel. The amount of cellular proteins was normalized to the amount of actin, visualized byWestern blotting (Actin
panel). (C) Viral titers in the cell culture supernatants determined at 24, 48, and 72 h postinfection. (D) Effect of HCV infection (top of each lane) on some host factors
involved in translationcontrol.Huh-7.5 cellswere infectedas indicated forpanelA, andat48and72hpostinfection, cell extractswereanalyzedbyWesternblottingusing
specific antibodies against eIF4G, eIF3a, eIF3b, eIF4B, PABP, and PTB proteins (as indicated to the right of each panel). (E) Phosphorylation levels of PKR and eIF2-
determined in the same protein extracts used as described for panels A, B, C, and D. Procedures are detailed inMaterials andMethods.
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volved in replicative-fitness enhancement. One of the mutants
under study includes substitutions N34D in E2, N17D in p7, and
Y618F in NS3 and displays increased resistance to IFN-, telapre-
vir, and daclatasvir but does not reach the same resistance level as
that seen with HCV p100 population.
The results presented here may help interpretation of HCV
treatment responses in vivo. High replicative fitness may allow
persistence of functional HCV RNAs in the face of antiviral treat-
ment, hence requiring higher drug concentrations or longer treat-
ment duration to achieve antiviral effects comparable to those
attained with a virus with low replicative fitness. A study per-
formed with patients subjected to daclatasvir monotherapy sug-
gested that viral fitness, rather than the presence of daclatasvir
resistance mutations, determined the dominance and persistence
of HCV variants following therapy (99). Prolonged replication of
HCV in the liver environment during chronic infection is ex-
pected to lead to an increase in viral fitness, thus suggesting that
chronicity and advanced liver disease may render the virus less
sensitive to antiviral treatment not only through accumulation of
inhibitor resistance mutations in an expanded mutant spectrum
but also through an increase in replicative fitness.
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